scholarly journals ID: 1033 Case report: Results of the first case of Stem cell transplantation from cord blood cryopreservation for β-thalassemia patient at Vinmec International Hospital

2017 ◽  
Vol 4 (S) ◽  
pp. 108
Author(s):  
Phu NT ◽  
Phuong T.M. Dam ◽  
Dung NT ◽  
Lan PT ◽  
Liem NT

Background: To report the result of first case of β thalassemia, which is successfully transplanted by using allogeneic cord blood at the Vinmec International Hospital.  Methods: Male patient, born in January 2014, was diagnosed with β thalassemia at 3 months of age. Patient was received cord blood transplantation from his younger sibling who matches HLA index of 10/10 in August 2016.  Results: The number of cells in cord blood met high quality and after 30 days of transplantation, engraftment of patient fully developed with the Chimerism test was 100%. After 3 months of follow-up, it was demonstrated that the transplantation was successful.  Conclusion: We present an effective case of hematopoietic stem cell transplantation from human umbilical cord blood of sibling for treatment of thalassemia.

Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 5497-5497
Author(s):  
Melhem M. Solh ◽  
Tori Smith ◽  
Jason Balls ◽  
Megan Smith ◽  
Yasser Khaled

Abstract Immune mediated demyelinating disease after allogeneic stem cell transplantation is a rare entity with unclear etiology. Acute inflammatory demyelinating polyneuropathy (AIDP) has been reported post related and unrelated allogeneic stem cell transplantation but no such case has been reported post unrelated cord blood transplantation. We hereby present the first case of GBS post double umbilical cord blood transplantation (DUCBT). A 55 year old male with relapsed refractory CLL received DUCBT with two 5/6 matched cord units (antigen level HLA-A, HLA-B and allele level HLA-DRB1) with fludarabine, cytoxan and total body irradiation based reduced intensity conditioning regimen. Graft versus host disease (GVHD) prophylaxis was with cyclosporine and mycophenolate. Early post transplant course was complicated by grade 4 acute GVHD of the gut with a complete resolution with steroid therapy and successful taper of all immunosuppression by day 180. 7 months post transplantation, patient presented with skin rash and tingling in both feet that progressed rapidly to lower extremity paralysis over the course of 2 days. Physical exam showed macula-papular rash affecting his upper extremities, upper chest and back area. Neurologic exam was significant for motor weakness in lower extremities 2/5, plantar flexion and knee flexion 3/5. He had loss of deep tendon reflexes in both lower extremities (Achilles and Patellar) and upper extremities (biceps and triceps).Workup revealed normal blood counts, organ function, vitamin B12, folate, TSH level, free cortisol. Serum electrophoresis and immunfixation was also normal. Magnetic resonance imaging of the central nervous system showed mild neural foramina narrowing at the L4-L5 level. Serology for Lyme disease, Epstein Bar virus (EBV), syphilis, cytomegalo virus (CMV), Hepatitis, HIV, toxoplasma, enterovirus and human herpes virus 6 was negative. Blood tests for autoimmune markers including (anti-nuclear antibody)ANA, acetylcholine esterase and volted calcium channel antibodies were normal. A lumbar puncture was performed and showed a high protein level of 67mg/dl, 1 nucleated cell/mm3 and normal glucose level. Cerebrospinal fluid was negative for oligoclonal bands, West Nile virus, cryptosporidium, HHV6, herpes virus 1 and 2, gram stain and cultures. Nerve conduction studies and needle electormyegraphy was suggestive of acute demyelinating polyneuropathy. Based on the above workup, he was diagnosed with GBS and started on therapy with intravenous immunoglobulin at 0.5gm/kg for 4 days and prednisone 1mg/kg daily for the treatment of GVHD. Etiology of GBS was presumed to be related to GVHD as his workup was negative for campylobacter, HIV and CMV. He improved significantly over the next 4 weeks and became ambulatory without assistance but his weakness symptoms relapsed as his prednisone was tapered. Prednisone was increased again to 1mg/kg and sirolimus was started. Patient was successfully tapered of prednisone and remains fully ambulatory without assistance or evidence of GVHD on single agent sirolimus 13 months post DUCBT. This is the first case of autoimmune demyelinating polyneuropathy post DUCBT with association of GVHD that was managed successfully with a combination of intravenous immunoglobulins, steroids and sirolimus. Disclosures: No relevant conflicts of interest to declare.


Hematology ◽  
2004 ◽  
Vol 2004 (1) ◽  
pp. 354-371 ◽  
Author(s):  
Nelson J. Chao ◽  
Stephen G. Emerson ◽  
Kenneth I. Weinberg

Abstract Allogeneic stem cell transplantation is an accepted treatment modality for selected malignant and non-malignant diseases. However, the ability to identify suitably matched related or unrelated donors can be difficult in some patients. Alternative sources of stem cells such as cord blood provide a readily available graft for such patients. Data accumulated over the past several years have demonstrated that the use of cord blood is an accepted source of stem cells for pediatric patients. Since the cell numbers of hematopoietic progenitors in cord blood is limited and the collection can occur only in a single occasion, its use in adult patients can be more problematic. Here, new developments in the use of cord blood for adults and studies aimed at expansion of cord blood cells and immune reconstitution are described. In Section I, Dr. Nelson Chao describes the early data in cord blood transplantation in adult patients. The patient outcomes are reviewed and analyzed for various factors such as cell dose, HLA typing, and patient selection that could have contributed to the final outcome of these adult patients. Myeloablative as well as nonmyeloablative approaches are presented. Discussion of the various benefits and risks are presented. More recent data from multiple single institutions as well as larger registry data comparisons are also provided. Analyses of these studies suggest methods to improve on the outcome. These newer data should lead to a logical progression in the use of cord blood cells in adult patients. In Section II, Dr. Stephen Emerson describes the historical efforts associated with expansion of hematopoietic stem cells, specifically with cord blood cells. These efforts to expand cord blood cells continue with novel methods. Moreover, a better understanding of stem cell biology and signaling is critical if we are to be able to effectively expand these cells for clinical use. An alternative, more direct, approach to expanding stem cells could be achieved by specific genetic pathways known or believed to support primitive HSC proliferation such as Notch-1 receptor activation, Wnt/LEF-1 pathway induction, telomerase or the Homeobox (Hox) gene products. The clinical experience with the use of expanded cord blood cells is also discussed. In Section III, Dr. Kenneth Weinberg describes immune reconstitution or lack thereof following cord blood transplantation. One of the hallmarks of successful hematopoietic stem cell transplantation is the ability to fully reconstitute the immune system of the recipient. Thus, the relationship between stem cell source and the development of T lymphocyte functions required for protection of the recipient from infection will be described, and cord blood recipients will be compared with those receiving other sources of stem cells. T cell development is described in detail, tracking from prethymic to postthymic lymphocytes with specific attention to umbilical cord blood as the source of stem cells. Moreover, a discussion of the placenta as a special microenvironment for umbilical cord blood is presented. Strategies to overcome the immunological defects are presented to improve the outcome of these recipients.


2014 ◽  
Vol 32 (30_suppl) ◽  
pp. 272-272 ◽  
Author(s):  
Jennifer Crombie ◽  
Laura Michelle Spring ◽  
Shuli Li ◽  
Robert Soiffer ◽  
Joseph Harry Antin ◽  
...  

272 Background: Readmission within 30 days of discharge has been perceived by the Centers for Medicare and Medicaid Services to be an indicator of poor healthcare quality, however it is unclear how accurately this applies to oncology patients. Patients treated with allogeneic hematopoietic stem cell transplantation (HSCT) have high rates of readmission, but the incidence following umbilical cord blood transplantation (UCBT) is poorly described. The goal of this study was to identify the incidence, reasons, and risk factors for readmission following UCBT. Methods: A retrospective review of patients receiving an UCBT at Dana-Farber/Brigham and Women’s Hospital between January 1, 2004 and December 31, 2013 was performed. The 30-day and the day +100, a traditional assessment point in transplantation, readmission rates were examined. Reasons for readmission, as well as sociodemographic and disease and stem cell transplant related variables were evaluated. Predictors of readmission were identified using multivariate regression analysis. Results: 33.6% (42/125) of patients were readmitted within 30 days of discharge. Of patients who survived until day +100, 46.7% (57/122) were readmitted within 100 days of UCBT. The most common cause for readmission was infection (38.3%), followed by fever without a source (14.8%) and graft vs. host disease (GVHD) (8.6%) (Table). A multivariate logistic regression model of the probability of being readmitted within 30 days and by day +100 suggested that infection during transplant admission was a significant risk factor for readmission (OR: 5.1, p=0.003 and OR: 2.9, p=0.014, respectively). Conclusions: There is a high rate of readmission within 30 days and by day +100 following UCBT. The most common causes of readmission were infection and fever without a source. Infection during the transplant admission predicted a higher risk of readmission, suggesting a possible group to target for interventions aimed at reducing readmissions and improving quality of care. [Table: see text]


Sign in / Sign up

Export Citation Format

Share Document